Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide Injection Device Pain Comparison
NCT04143945Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2019
- Primary completion
- Jan 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of semaglutide in type 2 diabetes mellitus (T2DM), obesity, sponsored by Novo Nordisk. Started Oct 2019; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT04143945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04143945.